Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | AKT2 |
| Gene Name: | AKT2 |
| Protein Full Name: | RAC-beta serine/threonine-protein kinase |
| Alias: | Akt2; EC 2.7.11.1; PKB beta; RAC-beta serine,threonine protein kinase; RAC-PK-beta |
| Mass (Da): | 55769 |
| Number AA: | 481 |
| UniProt ID: | P31751 |
| Locus ID: | 208 |
| COSMIC ID: | AKT2 |
| Gene location on chromosome: | 19q13 |
| Cancer protein type: | OP |
| Effect of cancer mutation on protein: | GAIN |
| Effect of active protein on cancer: | PROMOTES |
| Number of cancer specimens: | 21442 |
| Percent of cancer specimens with mutations: | 0.39 |
| Found in amplified chromosomal regions in human cancers: | Pancreatic, ovarian cancers (30%) |
| Normal role description: | AKT2 is a protein-serine/threonine kinase. It is closely related to AKT1 and AKT3. Its cell signalling activities involve activating cell surival and proliferation, increasing metabolism, and angiogenesis. Its interaction network contains over 100 substrates which includes inhibiting p53 via downstream signalling, activating mTOR, inhibition of GSK3B, and inhibition of cyclins. In cancer, it is found to be overexpressed and amplified. It is also linked with invasion, cell migration and induction of angiogenesis. |